An intranasal composition as unit dosage, comprising tapentadol or a pharmaceutically acceptable salt thereof in an amount that is equivalent to about 19.3 mg tapentadol free base； and at least one nasal carrier. After intranasal administration to the human a tapentadol mean Cmax-value achieved by said unit dose is equivalent to or greater than a tapentadol mean Cmax-value achieved by orally administering to the human an immediate release composition comprising tapentadol or a pharmaceutically acceptable salt thereof in an amount that is equivalent to 50 mg tapentadol free base.
